Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Net Income (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Net Income data on record, last reported at -$9.8 million in Q4 2025.

  • For Q4 2025, Net Income rose 3.51% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$39.2 million, down 30.62%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • Net Income reached -$9.8 million in Q4 2025 per TLSI's latest filing, up from -$10.8 million in the prior quarter.
  • Across five years, Net Income topped out at $2.8 million in Q1 2022 and bottomed at -$44.3 million in Q4 2022.
  • Average Net Income over 4 years is -$11.0 million, with a median of -$9.0 million recorded in 2025.
  • The widest YoY moves for Net Income: up 82.39% in 2023, down 686.85% in 2023.
  • A 4-year view of Net Income shows it stood at -$44.3 million in 2022, then rose by 19.5% to -$35.7 million in 2023, then surged by 71.68% to -$10.1 million in 2024, then increased by 3.51% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$9.8 million in Q4 2025, -$10.8 million in Q3 2025, and -$8.3 million in Q2 2025.